ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany

Rheumatology (United Kingdom)

Volumn 55, Issue 4, 2016, Pages 624-635

  Iking Konert, Christof ^a   Von Hinüber, Ulrich ^b   Richter, Constanze ^b   Schwenke, Holger ^b   Gürtler, Irmgard ^b   Kästner, Peter ^b   Klapperich, Birgit ^c   Peters, Marvin A ^d   Burmester, Gerd Rüdiger ^e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Roche Diagnostics International Ltd ^*  (Germany)

^c Roche Diagnostics International Ltd   (Switzerland)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibodies; Biological products; Germany; Humanized; Interleukin 6; Monoclonal; Observational study; Rheumatoid arthritis; Treatment outcome

Indexed keywords

ABATACEPT; ADALIMUMAB; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BRONCHITIS; BURSITIS; DAS28; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYSIPELAS; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GERMANY; HEADACHE; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PERIODONTITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; REMISSION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SALMONELLOSIS; SINUSITIS; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 84963741145     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev372     Document Type: Article

References (23)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
4. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
5. Kremer J, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
6. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
7. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
8. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
9. Burmester GR, Rubbert-Roth A, Cantagrel A et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
10. Kivitz A, Olech E, Borofsky M et al. Subcutaneous tocilizumab versus placebo in combination with diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:1653-61.
11. Burmester GR, Feist E, Kellner H et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.
12. Iking-Konert C, Aringer M, Wollenhaupt J et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90.
13. Bykerk VP, Ostor AJ, Alvaro-Gracia J et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4.
14. Zink A, Strangfeld A, Schneider M et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407.
15. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. van der Heijde DM, van 't Hof MA, van Riel PL et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
17. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-9.
18. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8.
19. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ, USA: John Wiley & Sons, Inc., 1987.
20. Ratitch B, Lipkovich I, O'Kelly M. Combining analysis results from multiply imputed categorical data. PharmaSUG 2013, 2013;1-19 (Paper SP03).
21. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
22. Schiff MH, Kremer JM, Jahreis A et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
23. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012;51:v38-47.